NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned

Publication
Article
OncologyONCOLOGY Vol 14 No 4
Volume 14
Issue 4

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The National Institutes of Health (NIH) is sponsoring a Consensus Development Conference on Adjuvant Therapy for Breast Cancer, to be held in Bethesda, Maryland, on November 1-3, 2000.

The conference will focus on new data on chemotherapy, hormonal therapy, and other aspects of treatment that have emerged over the past decade since the last consensus conference, and will culminate in the formulation of recommendations for clinical practice.

During the conference, a panel of experts (from outside of the NIH) will hear presentations from leading researchers and then consider questions on specific topics, such as the selection of chemotherapy, radiation therapy, and hormonal therapy. The agenda will also include the clinical use of prognostic markers and quality-of-life issues. Both node-negative and node-positive breast cancers will be discussed.

Health professionals, researchers, patient advocates, and other members of the public may register to attend the by sending an e-mail to breastcancer@prospectassoc.com or by going to the NIH web site for consensus conferences found at http://odp.od.nih.gov/consensus. Additional information is available by calling (301) 592-3320.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.